The kynurenine 3-hydroxylase inhibitor Ro 61-8048 improves dystonia in a genetic model of paroxysmal dyskinesia

European Journal of Pharmacology

Volumn 478, Issue 1, 2003, Pages 47-52

  Richter, Angelika ^a   Hamann, Melanie ^a  

^a FREIE UNIVERSITÄT BERLIN   (Germany)

Author keywords

Choreoathetosis; Dyskinesia; Glutamate; Kynurenic acid; Kynurenine hydroxylase; Movement disorder

Indexed keywords

3,4 DIMETHOXY N [4 (3 NITROPHENYL) 2 THIAZOLYL]BENZENESULFONAMIDE; 3,4 DIMETHOXY N [4 (3 NITROPHENYL)THIAZOL 2 YL]BENZENESULFONAMIDE; BENZENESULFONAMIDE DERIVATIVE; ENZYME INHIBITOR; GLUTAMATE RECEPTOR ANTAGONIST; KYNURENIC ACID; KYNURENINE 3 MONOOXYGENASE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BRAIN HOMOGENATE; BRAIN STEM; CEREBELLUM; CONTROLLED STUDY; CORPUS STRIATUM; DISEASE SEVERITY; DOSE RESPONSE; DRUG EFFECT; DYSKINESIA; DYSTONIA; FEMALE; GENETIC MODEL; HAMSTER; MALE; NONHUMAN; PRIORITY JOURNAL; STRESS;

ANIMALS; CHOREATIC DISORDERS; CRICETINAE; DISEASE MODELS, ANIMAL; DOSE-RESPONSE RELATIONSHIP, DRUG; DYSTONIA; ENZYME INHIBITORS; FEMALE; KYNURENINE 3-MONOOXYGENASE; MALE; MESOCRICETUS; MIXED FUNCTION OXYGENASES; SULFONAMIDES; THIAZOLES;

EID: 1642297574     PISSN: 00142999     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ejphar.2003.08.038     Document Type: Article

References (31)

1. sz mutants. J. Neurosci. 21(1-4):2001;RC153.
2. Carpenedo R., Pittaluga A., Cozzi A., Attucci S., Galli A., Reiteri M., Moroni F., Chiarugi A., Moroni F. Quinolinic acid formation in immune-activated mice: studies with (m-nitrobenzoyl)-alanine (mNBA) and 3,4-dimethoxy-[N-4-(3- nitrophenyl)thiazol-2-yl]-benzenesulfonamide (Ro 61-8048), two potent and selective inhibitors of kynurenine hydroxylase. Neuropharmacology. 38:1999;692-698.
3. Carpenedo R., Meli E., Peruginelli F., Domenico E., Pellegrini- Giampietro D.E., Moroni F. Kynurenine 3-mono-oxygenase inhibitors attenuate post-ischemic neuronal death in organotypic hippocampal slice cultures. J. Neurochem. 82:2002;1465-1471.
4. Chiarugi A., Moroni F. Quinolinic acid formation in immune-activated mice: studies with (m-nitrobenzoyl)-alanine (mNBA) and 3,4-dimethoxy-[-N-4-(3- nitrophenyl)thiazol-2yl]-benzenesulfonamide (Ro 61-8084), two potent and selective inhibitors of kynurenine hydroxylase. Neuropharmacology. 38:1999;1225-1233.
5. Cozzi A., Carpenedo R., Moroni F. Kynurenine hydroxylase inhibitors reduce ischemic brain damage: studies with (m-nitrobenzoyl)-alanine (mNBA) and 3,4-dimethoxy-[N-4-(3-nitrophenyl)thiazol-2-yl]-benzenesulfonamide (Ro 61-8048) in models of focal or global brain ischemia. J. Cereb. Blood Flow Metab. 19:1999;771-777.
6. Fredow G., Löscher W. Effects of pharmacological manipulation of GABAergic neurotransmission in a new mutant hamster model of paroxysmal dystonia. Eur. J. Pharmacol. 192:1991;207-219.
7. Gernert M., Hamann M., Bennay M., Löscher W., Richter A. Deficit of striatal parvalbumin-reactive GABAergic interneurons and decreased basal ganglia output in a genetic rodent model of idiopathic paroxysmal dystonia. J. Neurosci. 20:2000;7052-7058.
8. Hamann M., Richter A. The kynurenine 3-hydroxylase inhibitor Ro 61-8048 exerts antidystonic effects and increases kynurenic acid levls in brains of genetically dystonic animals. Naunyn-Schmiedeberg's Arch. Pharmacol. 365(Suppl. 1):2002;R87. (333).
9. Löscher W., Hörstermann D. Abnormalities in amino acid neurotransmitters in discrete brain regions of genetically dystonic hamsters. J. Neurochem. 59:1992;689-694.
10. Löscher W., Richter A. The glycine/NMDA receptor ligand (+)-HA-966 but not D-cycloserine exert antidystonic efficacy in a genetic animal model of dystonia. Eur. J. Pharmacol. 239:1993;245-247.
11. Löscher W., Fisher J.E. Jr., Schmidt D., Fredow G., Hönack D., Iturrian W.B. The sz mutant hamster: a genetic model of epilepsy or of paroxysmal dystonia? Mov. Disord. 4:1989;219-232.
12. Moroni F. Tryptophan metabolism and brain function: focus on kynurenine and other indole metabolites. Eur. J. Pharmacol. 375:1999;87-100.
13. Nardocci N., Fernandez-Alvarez E., Wood N.W., Spacy S.D., Richter A. The paroxysmal dyskinesias. Guerrini R., Aicardi J., Andermann F., Hallett M. Epilepsy and Movement Disorders. 2002;125-139 Cambridge Univ. Press, Cambridge.
14. Nobrega J.N., Richter A., Jiwa D., Raymond R., Löscher W. Autoradiographic analysis of NMDA receptor binding in dystonic hamster brains. Brain Res. 744:1997;161-165.
15. Nobrega J.N., Raymond R., Barlow K., Hamann M., Richter A. Changes in AMPA receptor binding in an animal model of inborn paroxysmal dystonia. Exp. Neurol. 176:2002;371-376.
16. Richter A., Hamann M. Effects of adenosine receptor agonists and antagonists in a genetic animal model of primary dystonia. Br. J. Pharmacol. 134:2001;343-352.
17. Richter A., Löscher W. Pathophysiology of idiopathic dystonia: findings from genetic animal models. Prog. Neurobiol. 54:1998;633-677.
18. Richter A., Löscher W. Animal models of paroxysmal dystonia. Adv. Neurol. 89:2002;443-451.
19. Richter A., Fredow G., Löscher W. Antidystonic effects of the NMDA receptor antagonists memantine, MK-801 and CGP 37849 in a mutant hamster model of paroxysmal dystonia. Neurosci. Lett. 133:1991;57-60.
20. Richter A., Löscher W., Löschmann P.-A. The AMPA receptor antagonist NBQX exerts antidystonic effects in an animal model of idiopathic dystonia. Eur. J. Pharmacol. 231:1993;287-291.
21. Richter A., Löscher W., Baran H., Gramer M. Increased levels of kynurenic acid in brains of genetically dystonic hamsters. Dev. Brain Res. 92:1996;111-116.
22. Richter A., Löschmann P.-A., Löscher W. Antidystonic efficacy of nitric oxide synthase inhibitors in a rodent model of primary paroxysmal dystonia. Br. J. Pharmacol. 131:2000;921-926.
23. Röver S., Cesura A.M., Hugenin P., Kettler R., Szente A. Synthesis and biochemical evaluation of N-(4-phenylthiazol-2-yl)benzenesulfonamides as high-affinity inhibitors of kynurenine 3-hydroxylase. J. Med. Chem. 40:1997;4378-4385.
24. Scharfman H.E., Goodman J.H., Schwarcz R. Electrophysiological effects of exogenous and endogenous kynurenic acid in the rat brain: studies in vivo and in vitro. Amino Acids. 19:2000;283-297.
25. Schwarcz R., Pellicciari R. Manipulation of brain kynurenines: glial targets, neuronal effects, and clinical opportunities. J. Pharmacol. Exp. Ther. 303:2002;1-10.
26. Stone T.W. Kynurenic acid antagonists and kynurenine pathway inhibitors. Expert Opin. Investig. Drugs. 45:2001;309-379.
27. Stone T.W. Kynurenines in the CNS: from endogenous obscurity to therapeutic importance. Prog. Neurobiol. 64:2001;185-218.
28. Swartz K.J., During M.J., Freese A., Beal M.F. Cerebral synthesis and release of kynurenic acid: an endogenous antagonist of excitatory amino acid receptors. J. Neurosci. 10:1990;2965-2973.
29. Urenjak J., Obrenovitch T.P. Kynurenine 3-hydroxylase inhibition in rats: effects on extracellular kynurenic acid concentration and N-methyl-D-aspartate- induced depolarization in the striatum. J. Neurochem. 75:2000;2427-2433.
30. Vitek J.L., Giroux M. Physiology of hypokinetic and hyperkinetic movement disorders: model for dyskinesia. Ann. Neurol. 47:2000;131-140.
31. Wu H.-Q., Guidetti P., Goodman J.H., Varasi M., Ceresoli-Borroni G., Speciale C., Scharfman H.E., Schwarcz R. Kynurenergic manipulations influence excitatory synaptic function and excitotoxic vulnerability in the rat hippocampus in vivo. Neuroscience. 97:2000;243-251.